PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30 p.m. Eastern Time.
加利福尼亚州圣何塞,2024年8月28日(环球新闻社) - 科普博机器人(纳斯达克:PRCT)(“公司”)是一家专注于推动泌尿科患者护理的外科机器人公司,致力于通过开发变革性的解决方案在泌尿外科领域取得进展。今天宣布,公司管理层将在位于马萨诸塞州波士顿举行的2024年富国银行医疗保健大会上发表演讲。管理层计划于9月4日星期三下午1:30东部时间发表演讲。
A live webcast of each event, as well as an archived recording, will be available on the "Investors" section of the company's website at: . The webcasts will be archived and available for replay for at least 90 days after the event.
公司网站的“投资者”部分将提供每个活动的现场网络广播以及存档记录:webcasts将存档,并在活动之后的至少90天内提供重播。
About PROCEPT BioRobotics Corporation
关于PROCEPT BioRobotics公司
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The HYDROSTM Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
科普博机器人是一家专注于推动泌尿科患者护理的外科机器人公司,通过开发变革性的解决方案来实现目标。HYDROSTm机器人系统是唯一的人工智能驱动的机器人技术,提供水切疗法。科普博机器人设计出水切疗法,以提供对因良性前列腺增生症导致的下尿路症状或LUTS的男性而言有效、安全且持久的疗效,而这些因素与前列腺大小和形状或外科医生的经验无关。BPH是最常见的前列腺疾病,影响着美国约4000万男性。公司已经积累了大量且不断增长的临床证据,有150多篇同行评议的出版物,支持水切疗法的益处和临床优势。
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
投资者联系人:
Matt Bacso
副总裁,投资者关系和业务运营
m.bacso@procept-biorobotics.com